The relation between cartilage biomarkers (C2C, C1,2C, CS846, and CPII) and the long-term outcome of rheumatoid arthritis patients within the CAMERA trial
The aim of this study was to investigate whether serum biomarker levels of C2C, C1,2C, CS846, and CPII can predict the long-term course of disease activity and radiographic progression early in the disease course of rheumatoid arthritis (RA). In patients in the CAMERA trial, levels of biomarkers wer...
Gespeichert in:
| Veröffentlicht in: | Arthritis research & therapy 2011-05, Vol.13 (3), p.R70-R70, Article R70 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | R70 |
|---|---|
| container_issue | 3 |
| container_start_page | R70 |
| container_title | Arthritis research & therapy |
| container_volume | 13 |
| creator | Bakker, Marije F Verstappen, Suzanne M M Welsing, Paco M J Jacobs, Johannes W G Jahangier, Zalima N van der Veen, Maaike J Bijlsma, Johannes W J Lafeber, Floris P J G |
| description | The aim of this study was to investigate whether serum biomarker levels of C2C, C1,2C, CS846, and CPII can predict the long-term course of disease activity and radiographic progression early in the disease course of rheumatoid arthritis (RA).
In patients in the CAMERA trial, levels of biomarkers were evaluated at baseline and after 1 year of treatment. Relations of (changes in) biomarker values with the mean yearly radiographic progression rate and mean disease activity over a 5-year period were evaluated by using regression analysis. The added predictive value of biomarkers over established predictors for long-term outcome was analyzed by multiple linear regression analysis.
Of 133 patients, serum samples were available at baseline and after 1 year of treatment. In the regression analysis C1,2C at baseline, the change in C2C, C1,2C, and the sum of the standardized changes in C2C + C1,2C scores were statistically significantly associated with the mean yearly radiographic progression rate; the change in CPII was associated with the mean disease activity over 5 years of treatment. In the multiple linear regression analysis, only the change in C1,2C was of added predictive value (P = 0.004) for radiographic progression. Explained variances of models for radiographic progression and disease activity were low (0.28 and 0.34, respectively), and the biomarkers only marginally improved the explained variance.
The change in C1,2C in the first year after onset of RA has a small added predictive value for disease severity over a 5-year period, but the predictive value of this biomarker combined with current predictive factors is too small to be of use for individual patients. |
| doi_str_mv | 10.1186/ar3331 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3218879</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A265232974</galeid><sourcerecordid>A265232974</sourcerecordid><originalsourceid>FETCH-LOGICAL-b482t-85f8630f1ebef06ec68c22a0136ed8dd7034c2a67b60f4e5db833bb2e5d99f9b3</originalsourceid><addsrcrecordid>eNptUm2L1DAQDuLhvag_QQKCeLA9m6RN0y_CUu68hRNFz88hSSfbaNssadbj_oq_1txWVxeOfJhh5nmeeckg9JLkF4QI_k4Fxhh5gk5IUYmMM06f7v2yOEan0_Q9zymtafEMHVNSsrqi9Qn6ddsBDtCr6PyINcQ7gBEbFaLr1Rqwdn5Q4QeECb9taLPADVnszFdR8AVWY4ubz6vV-c6LSav34zqLEAbst9H4AbC3OHSwHVT0rsVJuQsuuglvUk0Y44TvXOzcuGM3y4-XX5Y4Bqf65-jIqn6CF3_sGfp2dXnbXGc3nz6smuVNpgtBYyZKKzjLLQENNudguDCUqpwwDq1o2ypnhaGKV5rntoCy1YIxrWny6trWmp2h97PuZqsHaE3qKaheboJLk99Lr5w8zIyuk2v_UzJKhKjqJFDPAg_LelzgMJPWIucPS9zXM3etepButD4hzOAmI5eUl5TRuioS6uIRVHotDM74EaxL8QPCm5lggp-mAHbfDcnlw8H8q__q_-H3sL8Xwn4DKcy8KA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The relation between cartilage biomarkers (C2C, C1,2C, CS846, and CPII) and the long-term outcome of rheumatoid arthritis patients within the CAMERA trial</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><creator>Bakker, Marije F ; Verstappen, Suzanne M M ; Welsing, Paco M J ; Jacobs, Johannes W G ; Jahangier, Zalima N ; van der Veen, Maaike J ; Bijlsma, Johannes W J ; Lafeber, Floris P J G</creator><creatorcontrib>Bakker, Marije F ; Verstappen, Suzanne M M ; Welsing, Paco M J ; Jacobs, Johannes W G ; Jahangier, Zalima N ; van der Veen, Maaike J ; Bijlsma, Johannes W J ; Lafeber, Floris P J G ; Utrecht Arthritis Cohort study group ; the Utrecht Arthritis Cohort study group</creatorcontrib><description>The aim of this study was to investigate whether serum biomarker levels of C2C, C1,2C, CS846, and CPII can predict the long-term course of disease activity and radiographic progression early in the disease course of rheumatoid arthritis (RA).
In patients in the CAMERA trial, levels of biomarkers were evaluated at baseline and after 1 year of treatment. Relations of (changes in) biomarker values with the mean yearly radiographic progression rate and mean disease activity over a 5-year period were evaluated by using regression analysis. The added predictive value of biomarkers over established predictors for long-term outcome was analyzed by multiple linear regression analysis.
Of 133 patients, serum samples were available at baseline and after 1 year of treatment. In the regression analysis C1,2C at baseline, the change in C2C, C1,2C, and the sum of the standardized changes in C2C + C1,2C scores were statistically significantly associated with the mean yearly radiographic progression rate; the change in CPII was associated with the mean disease activity over 5 years of treatment. In the multiple linear regression analysis, only the change in C1,2C was of added predictive value (P = 0.004) for radiographic progression. Explained variances of models for radiographic progression and disease activity were low (0.28 and 0.34, respectively), and the biomarkers only marginally improved the explained variance.
The change in C1,2C in the first year after onset of RA has a small added predictive value for disease severity over a 5-year period, but the predictive value of this biomarker combined with current predictive factors is too small to be of use for individual patients.</description><identifier>ISSN: 1478-6354</identifier><identifier>EISSN: 1478-6362</identifier><identifier>EISSN: 1478-6354</identifier><identifier>DOI: 10.1186/ar3331</identifier><identifier>PMID: 21539729</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Adult ; Aged ; Antirheumatic Agents - therapeutic use ; Arthritis, Rheumatoid - blood ; Arthritis, Rheumatoid - diagnostic imaging ; Arthritis, Rheumatoid - drug therapy ; Biological markers ; Biomarkers - blood ; Care and treatment ; Cartilage - diagnostic imaging ; Cartilage - metabolism ; Diagnosis ; Disease Progression ; Female ; Follow-Up Studies ; Health aspects ; Humans ; Linear Models ; Male ; Methotrexate - therapeutic use ; Middle Aged ; Patient outcomes ; Predictive Value of Tests ; Prospective Studies ; Radiography ; Rheumatoid arthritis ; Severity of Illness Index ; Time ; Treatment Outcome</subject><ispartof>Arthritis research & therapy, 2011-05, Vol.13 (3), p.R70-R70, Article R70</ispartof><rights>COPYRIGHT 2011 BioMed Central Ltd.</rights><rights>Copyright ©2011 Bakker et al.; licensee BioMed Central Ltd. 2011 Bakker et al.; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b482t-85f8630f1ebef06ec68c22a0136ed8dd7034c2a67b60f4e5db833bb2e5d99f9b3</citedby><cites>FETCH-LOGICAL-b482t-85f8630f1ebef06ec68c22a0136ed8dd7034c2a67b60f4e5db833bb2e5d99f9b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218879/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218879/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21539729$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bakker, Marije F</creatorcontrib><creatorcontrib>Verstappen, Suzanne M M</creatorcontrib><creatorcontrib>Welsing, Paco M J</creatorcontrib><creatorcontrib>Jacobs, Johannes W G</creatorcontrib><creatorcontrib>Jahangier, Zalima N</creatorcontrib><creatorcontrib>van der Veen, Maaike J</creatorcontrib><creatorcontrib>Bijlsma, Johannes W J</creatorcontrib><creatorcontrib>Lafeber, Floris P J G</creatorcontrib><creatorcontrib>Utrecht Arthritis Cohort study group</creatorcontrib><creatorcontrib>the Utrecht Arthritis Cohort study group</creatorcontrib><title>The relation between cartilage biomarkers (C2C, C1,2C, CS846, and CPII) and the long-term outcome of rheumatoid arthritis patients within the CAMERA trial</title><title>Arthritis research & therapy</title><addtitle>Arthritis Res Ther</addtitle><description>The aim of this study was to investigate whether serum biomarker levels of C2C, C1,2C, CS846, and CPII can predict the long-term course of disease activity and radiographic progression early in the disease course of rheumatoid arthritis (RA).
In patients in the CAMERA trial, levels of biomarkers were evaluated at baseline and after 1 year of treatment. Relations of (changes in) biomarker values with the mean yearly radiographic progression rate and mean disease activity over a 5-year period were evaluated by using regression analysis. The added predictive value of biomarkers over established predictors for long-term outcome was analyzed by multiple linear regression analysis.
Of 133 patients, serum samples were available at baseline and after 1 year of treatment. In the regression analysis C1,2C at baseline, the change in C2C, C1,2C, and the sum of the standardized changes in C2C + C1,2C scores were statistically significantly associated with the mean yearly radiographic progression rate; the change in CPII was associated with the mean disease activity over 5 years of treatment. In the multiple linear regression analysis, only the change in C1,2C was of added predictive value (P = 0.004) for radiographic progression. Explained variances of models for radiographic progression and disease activity were low (0.28 and 0.34, respectively), and the biomarkers only marginally improved the explained variance.
The change in C1,2C in the first year after onset of RA has a small added predictive value for disease severity over a 5-year period, but the predictive value of this biomarker combined with current predictive factors is too small to be of use for individual patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Arthritis, Rheumatoid - blood</subject><subject>Arthritis, Rheumatoid - diagnostic imaging</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Biological markers</subject><subject>Biomarkers - blood</subject><subject>Care and treatment</subject><subject>Cartilage - diagnostic imaging</subject><subject>Cartilage - metabolism</subject><subject>Diagnosis</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Linear Models</subject><subject>Male</subject><subject>Methotrexate - therapeutic use</subject><subject>Middle Aged</subject><subject>Patient outcomes</subject><subject>Predictive Value of Tests</subject><subject>Prospective Studies</subject><subject>Radiography</subject><subject>Rheumatoid arthritis</subject><subject>Severity of Illness Index</subject><subject>Time</subject><subject>Treatment Outcome</subject><issn>1478-6354</issn><issn>1478-6362</issn><issn>1478-6354</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptUm2L1DAQDuLhvag_QQKCeLA9m6RN0y_CUu68hRNFz88hSSfbaNssadbj_oq_1txWVxeOfJhh5nmeeckg9JLkF4QI_k4Fxhh5gk5IUYmMM06f7v2yOEan0_Q9zymtafEMHVNSsrqi9Qn6ddsBDtCr6PyINcQ7gBEbFaLr1Rqwdn5Q4QeECb9taLPADVnszFdR8AVWY4ubz6vV-c6LSav34zqLEAbst9H4AbC3OHSwHVT0rsVJuQsuuglvUk0Y44TvXOzcuGM3y4-XX5Y4Bqf65-jIqn6CF3_sGfp2dXnbXGc3nz6smuVNpgtBYyZKKzjLLQENNudguDCUqpwwDq1o2ypnhaGKV5rntoCy1YIxrWny6trWmp2h97PuZqsHaE3qKaheboJLk99Lr5w8zIyuk2v_UzJKhKjqJFDPAg_LelzgMJPWIucPS9zXM3etepButD4hzOAmI5eUl5TRuioS6uIRVHotDM74EaxL8QPCm5lggp-mAHbfDcnlw8H8q__q_-H3sL8Xwn4DKcy8KA</recordid><startdate>20110508</startdate><enddate>20110508</enddate><creator>Bakker, Marije F</creator><creator>Verstappen, Suzanne M M</creator><creator>Welsing, Paco M J</creator><creator>Jacobs, Johannes W G</creator><creator>Jahangier, Zalima N</creator><creator>van der Veen, Maaike J</creator><creator>Bijlsma, Johannes W J</creator><creator>Lafeber, Floris P J G</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20110508</creationdate><title>The relation between cartilage biomarkers (C2C, C1,2C, CS846, and CPII) and the long-term outcome of rheumatoid arthritis patients within the CAMERA trial</title><author>Bakker, Marije F ; Verstappen, Suzanne M M ; Welsing, Paco M J ; Jacobs, Johannes W G ; Jahangier, Zalima N ; van der Veen, Maaike J ; Bijlsma, Johannes W J ; Lafeber, Floris P J G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b482t-85f8630f1ebef06ec68c22a0136ed8dd7034c2a67b60f4e5db833bb2e5d99f9b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Arthritis, Rheumatoid - blood</topic><topic>Arthritis, Rheumatoid - diagnostic imaging</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Biological markers</topic><topic>Biomarkers - blood</topic><topic>Care and treatment</topic><topic>Cartilage - diagnostic imaging</topic><topic>Cartilage - metabolism</topic><topic>Diagnosis</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Linear Models</topic><topic>Male</topic><topic>Methotrexate - therapeutic use</topic><topic>Middle Aged</topic><topic>Patient outcomes</topic><topic>Predictive Value of Tests</topic><topic>Prospective Studies</topic><topic>Radiography</topic><topic>Rheumatoid arthritis</topic><topic>Severity of Illness Index</topic><topic>Time</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bakker, Marije F</creatorcontrib><creatorcontrib>Verstappen, Suzanne M M</creatorcontrib><creatorcontrib>Welsing, Paco M J</creatorcontrib><creatorcontrib>Jacobs, Johannes W G</creatorcontrib><creatorcontrib>Jahangier, Zalima N</creatorcontrib><creatorcontrib>van der Veen, Maaike J</creatorcontrib><creatorcontrib>Bijlsma, Johannes W J</creatorcontrib><creatorcontrib>Lafeber, Floris P J G</creatorcontrib><creatorcontrib>Utrecht Arthritis Cohort study group</creatorcontrib><creatorcontrib>the Utrecht Arthritis Cohort study group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Arthritis research & therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bakker, Marije F</au><au>Verstappen, Suzanne M M</au><au>Welsing, Paco M J</au><au>Jacobs, Johannes W G</au><au>Jahangier, Zalima N</au><au>van der Veen, Maaike J</au><au>Bijlsma, Johannes W J</au><au>Lafeber, Floris P J G</au><aucorp>Utrecht Arthritis Cohort study group</aucorp><aucorp>the Utrecht Arthritis Cohort study group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The relation between cartilage biomarkers (C2C, C1,2C, CS846, and CPII) and the long-term outcome of rheumatoid arthritis patients within the CAMERA trial</atitle><jtitle>Arthritis research & therapy</jtitle><addtitle>Arthritis Res Ther</addtitle><date>2011-05-08</date><risdate>2011</risdate><volume>13</volume><issue>3</issue><spage>R70</spage><epage>R70</epage><pages>R70-R70</pages><artnum>R70</artnum><issn>1478-6354</issn><eissn>1478-6362</eissn><eissn>1478-6354</eissn><abstract>The aim of this study was to investigate whether serum biomarker levels of C2C, C1,2C, CS846, and CPII can predict the long-term course of disease activity and radiographic progression early in the disease course of rheumatoid arthritis (RA).
In patients in the CAMERA trial, levels of biomarkers were evaluated at baseline and after 1 year of treatment. Relations of (changes in) biomarker values with the mean yearly radiographic progression rate and mean disease activity over a 5-year period were evaluated by using regression analysis. The added predictive value of biomarkers over established predictors for long-term outcome was analyzed by multiple linear regression analysis.
Of 133 patients, serum samples were available at baseline and after 1 year of treatment. In the regression analysis C1,2C at baseline, the change in C2C, C1,2C, and the sum of the standardized changes in C2C + C1,2C scores were statistically significantly associated with the mean yearly radiographic progression rate; the change in CPII was associated with the mean disease activity over 5 years of treatment. In the multiple linear regression analysis, only the change in C1,2C was of added predictive value (P = 0.004) for radiographic progression. Explained variances of models for radiographic progression and disease activity were low (0.28 and 0.34, respectively), and the biomarkers only marginally improved the explained variance.
The change in C1,2C in the first year after onset of RA has a small added predictive value for disease severity over a 5-year period, but the predictive value of this biomarker combined with current predictive factors is too small to be of use for individual patients.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>21539729</pmid><doi>10.1186/ar3331</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1478-6354 |
| ispartof | Arthritis research & therapy, 2011-05, Vol.13 (3), p.R70-R70, Article R70 |
| issn | 1478-6354 1478-6362 1478-6354 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3218879 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; PubMed Central; SpringerLink Journals - AutoHoldings; PubMed Central Open Access; Springer Nature OA Free Journals |
| subjects | Adult Aged Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - blood Arthritis, Rheumatoid - diagnostic imaging Arthritis, Rheumatoid - drug therapy Biological markers Biomarkers - blood Care and treatment Cartilage - diagnostic imaging Cartilage - metabolism Diagnosis Disease Progression Female Follow-Up Studies Health aspects Humans Linear Models Male Methotrexate - therapeutic use Middle Aged Patient outcomes Predictive Value of Tests Prospective Studies Radiography Rheumatoid arthritis Severity of Illness Index Time Treatment Outcome |
| title | The relation between cartilage biomarkers (C2C, C1,2C, CS846, and CPII) and the long-term outcome of rheumatoid arthritis patients within the CAMERA trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T03%3A32%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20relation%20between%20cartilage%20biomarkers%20(C2C,%20C1,2C,%20CS846,%20and%20CPII)%20and%20the%20long-term%20outcome%20of%20rheumatoid%20arthritis%20patients%20within%20the%20CAMERA%20trial&rft.jtitle=Arthritis%20research%20&%20therapy&rft.au=Bakker,%20Marije%20F&rft.aucorp=Utrecht%20Arthritis%20Cohort%20study%20group&rft.date=2011-05-08&rft.volume=13&rft.issue=3&rft.spage=R70&rft.epage=R70&rft.pages=R70-R70&rft.artnum=R70&rft.issn=1478-6354&rft.eissn=1478-6362&rft_id=info:doi/10.1186/ar3331&rft_dat=%3Cgale_pubme%3EA265232974%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/21539729&rft_galeid=A265232974&rfr_iscdi=true |